The momentum experienced in H2 last year continued into H1, with further strong top line growth in the period YoY. The core pre-clinical market remains supportive and momentum continues to build around the SEND initiative, where Instem has maintained its market leading position. Two acquisitions have now been completed following the £5.0m placing in February, strengthening Instem’s strategic position and adding materially to our growth forecasts. The valuation remains undemanding on an FY17 EV/ ....